ReviewFrontiers in cardiovascular medicine2020
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management.
Review in Frontiers in cardiovascular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06619353 (Residual CardioVascular Risk), which is not on this map. Cited by 105 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Residual CardioVascular Risk (RCVR) After Percutaneous Coronary Intervention: A Prospective Study
Who cites it
105 citing papers in PubMed, 169 citations in OpenAlex.
- A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.Journal of the American Heart Association · 2022Trial
- A Cathepsin-Triggered Size-Shrinkable Nanoparticle Enhances Fibrous Cap Penetration to Relieve Atherosclerosis.Advanced healthcare materials · 2026Article
- Lipoprotein(a) Levels and Major Adverse Cardiovascular Events in Alberta, Canada: A Retrospective Cohort Study.CJC open · 2026Article
- Dynamic Complement Activation Predicts 12-Month Major Adverse Cardiovascular Events in Acute Coronary Syndromes.Biomedicines · 2026Article
- Right Atrial Cardiac Calcified Amorphous Tumors in Young Women: Two Case Reports and a Narrative Review of the Literature.Journal of cardiovascular development and disease · 2026Review
- The synergistic pattern of metabolic-inflammatory changes jointly predicts cardiovascular risk in Chinese middle-aged and older adults: a prospective cohort study.Scientific reports · 2026Article
- Lipoprotein(a)-associated proteomic signature predicts cardiovascular disease in young adults.The Journal of clinical investigation · 2026Observational
- Relationship between culprit lesion high-risk plaque features and adverse cardiovascular outcome at two years follow-up in patients with acute coronary syndrome. Insights from the OPTICO-ACS study.The international journal of cardiovascular imaging · 2026Observational
- Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.American journal of preventive cardiology · 2026Article
- Sex differences in vascular endothelial function in predicting cardiovascular events in hypertensive patients.Internal and emergency medicine · 2026Article
- Association of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose and its modified indices with cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a longitudinal analysis based on CHARLS.Cardiovascular diabetology · 2026Observational
- Association of triglyceride-driven residual atherosclerotic risk with carotid stiffening assessed using ultrafast ultrasound imaging in individuals with hypertriglyceridemia.Ultrasonography (Seoul, Korea) · 2026Article
- Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT.Current atherosclerosis reports · 2026Review
- Prognostic value of a novel indicator integrating C-reactive protein-triglyceride glucose index and coronary physiological burden in patients undergoing PCI: a prospective cohort study.Frontiers in nutrition · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and incident cardiovascular disease in middle-aged and older adults with arthritis: a nationwide prospective cohort study with hospital-based cross-sectional replication.Frontiers in immunology · 2026Article
- Genistein Restores Nitric Oxide Bioavailability and Attenuates Oxidative Stress in Angiotensin II-Induced Hypertensive Mice.Preventive nutrition and food science · 2026Article
- Evolocumab early reduces IL-1β/IL-17A and improves left ventricular function in STEMI: an observational study in the real world.Frontiers in pharmacology · 2026Article
- Beyond metabolism and blood flow: toward an inflammation-metabolism axis paradigm for herbal medicine in obesity-related coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Editorial: Residual cardiovascular risk in diabetes: current state and future perspectives.Frontiers in clinical diabetes and healthcare · 2026Article
- The C-reactive protein-triglyceride glucose index (CTI) predicts mortality in cardiovascular-kidney-metabolic syndrome: a dual-cohort study with machine learning validation.International journal of surgery (London, England) · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite unprecedented advances in treatment of atherosclerotic cardiovascular disease, it remains the leading cause of death and disability worldwide. Treatment of major traditional risk factors, including low-density lipoprotein-cholesterol, serves as the foundation of atherosclerotic risk reduction. However, there remains a significant residual risk of cardiovascular events despite optimal risk factor management. Beyond traditional risk factors, other drivers of residual risk have come to the forefront, including inflammatory, pro-thrombotic, and metabolic pathways that contribute to recurrent events and are often unrecognized and not addressed in clinical practice. This review will explore the evidence linking these pathways to atherosclerotic cardiovascular disease and potential future therapeutic options to attenuate residual cardiovascular risk conferred by these pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.